Comparison of two low-density lipoprotein apheresis systems in patients with homozygous familial hypercholesterolemia

Jean-Philippe Drouin-Chartier1, André J Tremblay1, Jean Bergeron2

  • 1Institute of Nutrition and Functional Foods, Laval University, Quebec City, Québec, Canada.

Insights

Dextran sulfate adsorption (DS) LDL apheresis (LA) significantly reduced lipids and inflammatory markers more effectively than heparin-induced extracorporeal LDL precipitation (HELP) in homozygous familial hypercholesterolemia (HoFH) patients. HELP showed greater reductions in apoB, HDL-C, and PCSK9 for the same filtered plasma volume.

Area of Science:

  • Cardiovascular Medicine
  • Medical Technology

Background:

  • Low-density lipoprotein (LDL) apheresis (LA) is crucial for managing homozygous familial hypercholesterolemia (HoFH).
  • Comparing different LA systems is essential for optimizing HoFH treatment.

Purpose of the Study:

  • To compare the efficacy of two LDL apheresis systems: heparin-induced extracorporeal LDL precipitation (HELP) and dextran sulfate adsorption (DS).
  • To evaluate the reduction of lipids, inflammatory markers, and adhesion molecules in HoFH patients using HELP versus DS.

Main Methods:

  • A single-sequence study involving 9 genetically defined HoFH subjects.
  • Each subject underwent both HELP and DS apheresis, serving as their own control.
  • Fasting blood samples were collected pre- and post-apheresis for analysis.

Main Results:

  • DS demonstrated significantly greater reductions in total cholesterol, LDL-C, C-reactive protein (CRP), and TNF-α compared to HELP.
  • No significant differences were observed between DS and HELP in reducing PCSK9, lipoprotein(a), E-selectin, ICAM-1, and VCAM-1.
  • For a filtered plasma volume of 3,000 mL, HELP achieved greater reductions in apoB, HDL-C, and PCSK9 than DS.

Conclusions:

  • Both HELP and DS apheresis systems are effective in reducing plasma lipids and inflammatory markers in HoFH.
  • DS achieved superior reductions in lipid levels and inflammatory markers, likely due to its ability to process a larger plasma volume.
  • The choice of apheresis system may influence the extent of lipid and inflammatory marker reduction in HoFH patients.

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
871
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
602
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K